LOCALLY ADVANCED PROSTATE CANCER
Clinical trials for LOCALLY ADVANCED PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED PROSTATE CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost prostate cancer cure rates
Disease control Recruiting nowThis early-phase trial tests whether taking relugolix and enzalutamide together before and after radiation or surgery can improve cure rates and delay cancer progression in men with high-risk locally advanced prostate cancer. About 46 participants will receive the drug combinatio…
Matched conditions: LOCALLY ADVANCED PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated May 17, 2026 13:53 UTC
-
Could a radiation boost stop prostate cancer from spreading?
Disease control Recruiting nowThis study tests whether giving a higher radiation dose directly to prostate tumors can reduce the chance of cancer spreading or returning. About 1,016 men with high-risk prostate cancer will be randomly assigned to receive either standard radiotherapy or standard radiotherapy pl…
Matched conditions: LOCALLY ADVANCED PROSTATE CANCER
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for advanced prostate cancer: drug may replace hormone therapy
Disease control Recruiting nowThis study tests whether adding the drug Pluvicto to standard radiation can lower the chance of prostate cancer coming back while avoiding the side effects of long-term hormone therapy. About 45 adults with advanced local prostate cancer will receive one or two doses of Pluvicto …
Matched conditions: LOCALLY ADVANCED PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Angela Y. Jia, MD PhD • Aim: Disease control
Last updated May 13, 2026 16:03 UTC